目的:探讨参麦注射液联合吉西他滨和顺铂对晚期非小细胞肺癌(NSCLC)患者肿瘤标志物、T淋巴细胞亚群和血清凋亡分子的影响。方法:将在2020年3月～2022年12月期间我院收治的118例晚期NSCLC患者以随机数字表法分为联合组(n=59，参麦注射液联合吉西他滨和顺铂治疗)和对照组(n=59，吉西他滨和顺铂治疗)。对比两组肿瘤标志物水平、T淋巴细胞亚群、凋亡分子。结果:与对照组相比，联合组治疗后细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、鳞状细胞癌相关抗原(SCC)、糖类抗原 125(CA125)、B 淋巴细胞瘤(Bcl-2)、生存素(Survivin)、CD8+更低，Bcl-2 相关 X 蛋白(Bax)、CD3+、CD4+、CD4+/CD8+更高(P＜0。05)。结论:参麦注射液联合吉西他滨和顺铂治疗晚期NSCLC患者，能够降低肿瘤标志物水平，减轻患者免疫抑制，调节血清凋亡分子水平。
Effects of Shenmai Injection Combined with Gemcitabine and Cisplatin on Tumor Markers,T Lymphocyte Subsets and Serum Apoptotic Molecules in Patients with Advanced NSCLC
Objective:To investigate the effects of shenmai injection combined with gemcitabine and cisplatin on tumor markers,T lymphocyte subsets and serum apoptotic molecules in patients with advanced non-small cell lung cancer(NSCLC).Methods:118 patients with advanced NSCLC who were admitted to our hospital from March 2020 to December 2022 were divided into combined group(n=59,treated with shenmai injection combined with gemcitabine and cisplatin)and control group(n=59,treated with gemcitabine and cisplatin)by random number table method.The tumor marker level,T lymphocyte subsets and apoptotic molecules were compared between two groups.Results:Compared with control group,cytokeratin 19 fragment(CYFRA21-1),carcinoembryonic antigen(CEA),sqamous cell carcinoma antigen(SCC),carbohydrate antigen 125(CA125),B-cell lymphoma(Bcl-2),Survivin(Survivin),CD8+were lower in combined group after treatment,and Bcl-2-related X protein(Bax)and CD3+,CD4+,CD4+/CD8+were higher(P＜0.05).Conclusion:Shenmai injection combined with gemcitabine and cisplatin for the treatment of advanced NSCLC Patients,which can reduce tumor markers level,reduce the immunosuppression of patients,regulate serum apoptotic molecules level.
NETL
NSTL
万方数据
